-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 9, Pfizer announced that it had reached a cooperation with Biohaven to introduce the company's rights and interests in the company's oral CGRP antagonist Rimegepant (Nurtec®ODT) outside the United States
.
In this transaction, Pfizer will pay a down payment of US$500 million, including US$150 million in cash and US$350 million to purchase Biohaven equity at a 25% market premium; potential milestone payments of up to US$740 million, and a concession based on net sales outside the US Royalties
At the same time, in this transaction, Pfizer also obtained the US rights and interests of Zavegepant, another small molecule CGRP receptor antagonist for the treatment of migraine
.
Zavegepant is a third-generation, high-affinity, selective CGRP receptor antagonist with a unique structure.
Rimegepant is the first oral CGRP receptor inhibitor approved for the preventive treatment of migraine and the only migraine drug approved for both acute treatment of migraine attacks and preventive treatment
.
The drug was first approved for marketing in February 2020 for the treatment of acute migraine; on May 27, 2021, it was approved for extended indications for episodic migraine (the number of migraine attacks per month is less than 15 ) Preventive treatment
According to Biohaven's financial report, its sales in 2021Q2 have reached 93 million U.
S.
dollars, a 112% increase compared to the first quarter; Q3 continued to grow to 136 million U.
S.
dollars
.
At present, its cumulative product sales have reached 336 million U.
According to statistics, migraine affects nearly 14% of the world's population.
There are approximately 33 million cases in the United States, 8 million cases in Japan, and 13 million cases in China
.
Compared with old drugs for acute migraine, CGRP receptor antagonists (gepants) and 5-HT1F receptor agonists (ditans) have the advantages of better curative effect and mild side effects
Currently, 6 CGRP/CGRPR inhibitors have been approved globally, with total sales reaching 1.
Domestic and international progress of CGRP inhibitors approved globally (Insight)
From Insight database (http://db.
However, the CGRP project of domestic enterprises has not yet entered the clinical stage, and the field is still a blue ocean
Original English: https://ir.
https://ir.
immunocore.
com/news-releases/news-release-details/immunocore-presents-new-data-tebentafusp-metastatic-cutaneous
